12:00 AM
Nov 12, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

HGT 1110: Phase I/II started

Shire disclosed in its 3Q12 earnings that it began the open-label, dose-escalation, European Phase I/II IDEAMLD trial to evaluate 10, 30 and 100 mg...

Read the full 100 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >